File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Methotrexate infusion in low-risk gestational trophoblastic disease

TitleMethotrexate infusion in low-risk gestational trophoblastic disease
Authors
Issue Date2000
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ajog
Citation
American Journal Of Obstetrics And Gynecology, 2000, v. 183 n. 6, p. 1579-1582 How to Cite?
AbstractOBJECTIVES: The current study attempts to evaluate the effectiveness of methotrexate infusion therapy in the management of low-risk gestational trophoblastic disease and to find out whether an increase in the dose intensity can effect a faster remission and a shorter treatment duration. STUDY DESIGN: This is a prospective study. Between June 1990 and August 1998, 59 patients with low-risk trophoblastic disease were treated with methotrexate at a dose of 100 mg/m 2 as an intravenous bolus over 30 minutes followed by a 12-hour infusion of methotrexate at a dose of 200 mg/m 2. Folinic acid was not given unless the serum methotrexate reached a toxic level 24 hours after infusion (toxic level, 10 μmol/L). Actinomycin D was added in patients with a partial response. The follow-up period of these patients ranged from 12 to 113 months, with a median of 58.5 months and a mean of 55.7 months. RESULTS: Fifty-four patients attained a complete biochemical remission. Twenty-eight patients went into biochemical remission after one methotrexate infusion. Five patients showed a partial biochemical response. A relapse developed in 2 of the 54 complete responders at 3 months and 18 months after the initial therapy. Both patients received combination therapy consisting of methotrexate, etoposide, and bleomycin. They went into biochemical remission and have remained disease-free at the time of analysis. All of the 59 patients were in biochemical remission at the time of analysis. No significant side effects were observed except that Stevens-Johnson syndrome developed in 1 patient. CONCLUSIONS: Methotrexate infusion therapy described in this study is effective in the treatment of low-risk gestational trophoblastic disease. The omission of consolidation therapy and folinic acid rescue decreases the cost and duration of treatment.
Persistent Identifierhttp://hdl.handle.net/10722/173246
ISSN
2015 Impact Factor: 4.681
2015 SCImago Journal Rankings: 2.255
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, LCen_US
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorCheng, DKLen_US
dc.contributor.authorNg, TYen_US
dc.date.accessioned2012-10-30T06:28:45Z-
dc.date.available2012-10-30T06:28:45Z-
dc.date.issued2000en_US
dc.identifier.citationAmerican Journal Of Obstetrics And Gynecology, 2000, v. 183 n. 6, p. 1579-1582en_US
dc.identifier.issn0002-9378en_US
dc.identifier.urihttp://hdl.handle.net/10722/173246-
dc.description.abstractOBJECTIVES: The current study attempts to evaluate the effectiveness of methotrexate infusion therapy in the management of low-risk gestational trophoblastic disease and to find out whether an increase in the dose intensity can effect a faster remission and a shorter treatment duration. STUDY DESIGN: This is a prospective study. Between June 1990 and August 1998, 59 patients with low-risk trophoblastic disease were treated with methotrexate at a dose of 100 mg/m 2 as an intravenous bolus over 30 minutes followed by a 12-hour infusion of methotrexate at a dose of 200 mg/m 2. Folinic acid was not given unless the serum methotrexate reached a toxic level 24 hours after infusion (toxic level, 10 μmol/L). Actinomycin D was added in patients with a partial response. The follow-up period of these patients ranged from 12 to 113 months, with a median of 58.5 months and a mean of 55.7 months. RESULTS: Fifty-four patients attained a complete biochemical remission. Twenty-eight patients went into biochemical remission after one methotrexate infusion. Five patients showed a partial biochemical response. A relapse developed in 2 of the 54 complete responders at 3 months and 18 months after the initial therapy. Both patients received combination therapy consisting of methotrexate, etoposide, and bleomycin. They went into biochemical remission and have remained disease-free at the time of analysis. All of the 59 patients were in biochemical remission at the time of analysis. No significant side effects were observed except that Stevens-Johnson syndrome developed in 1 patient. CONCLUSIONS: Methotrexate infusion therapy described in this study is effective in the treatment of low-risk gestational trophoblastic disease. The omission of consolidation therapy and folinic acid rescue decreases the cost and duration of treatment.en_US
dc.languageengen_US
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ajogen_US
dc.relation.ispartofAmerican Journal of Obstetrics and Gynecologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntimetabolites, Antineoplastic - Therapeutic Useen_US
dc.subject.meshAntineoplastic Agents, Phytogenic - Therapeutic Useen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshBleomycin - Therapeutic Useen_US
dc.subject.meshEtoposide - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHydatidiform Mole - Drug Therapyen_US
dc.subject.meshInfusions, Intravenousen_US
dc.subject.meshMethotrexate - Therapeutic Useen_US
dc.subject.meshNeoplasm Recurrence, Local - Drug Therapyen_US
dc.subject.meshPregnancyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshRisk Factorsen_US
dc.titleMethotrexate infusion in low-risk gestational trophoblastic diseaseen_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1067/mob.2000.108077en_US
dc.identifier.pmid11120531-
dc.identifier.scopuseid_2-s2.0-0034519035en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034519035&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume183en_US
dc.identifier.issue6en_US
dc.identifier.spage1579en_US
dc.identifier.epage1582en_US
dc.identifier.isiWOS:000165952000053-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWong, LC=7402092003en_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridCheng, DKL=7402806161en_US
dc.identifier.scopusauthoridNg, TY=7402229853en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats